Jazz Pharma director plans $858K stock sale

Jazz Pharmaceuticals plc (JAZZ) is the issuer of common stock referenced in a notice of proposed sale filed for the account of Patrick G. Enright under Rule 144.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) is the issuer of common stock referenced in a notice of proposed sale filed for the account of Patrick G. Enright under Rule 144. The notice covers a proposed sale of 3,507 shares of JAZZ common stock held at E*TRADE Financial Corporation.

The securities relate to restricted stock vesting designated as compensation, with an aggregate market value stated as $857,602.00. The Form 144 identifies the proposed sale date as August 31, 2026, with the transaction to occur on NASDAQ.

Key Figures

Shares proposed to be sold: 3,507 shares Aggregate market value: $857,602.00 Proposed sale date: August 31, 2026 +1 more

4 metrics

Shares proposed to be sold 3,507 shares Common stock covered by the Form 144 notice for Patrick G. Enright

Aggregate market value $857,602.00 Aggregate market value of 3,507 JAZZ common shares listed in the notice

Proposed sale date August 31, 2026 Date indicated for the proposed sale of JAZZ common shares on NASDAQ

Security type Common stock Class of Jazz Pharmaceuticals plc securities referenced in the filing

Key Terms

Form 144, Rule 144, restricted stock vesting, compensation

4 terms

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock vesting financial

"COMMON | 08/28/2026 | RESTRICTED STOCK VESTING | ISSUER"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

compensation financial

"08/28/2026 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for JAZZ disclose about planned stock sales?

The Form 144 notice discloses a proposed sale of 3,507 shares of Jazz Pharmaceuticals plc common stock for the account of Patrick G. Enright, with an aggregate market value of $857,602.00, expected to be sold on August 31, 2026 on NASDAQ.

Who is the person planning to sell JAZZ shares under this Form 144?

The planned sale of Jazz Pharmaceuticals plc (JAZZ) common stock is for the account of Patrick G. Enright, identified as a director. The shares are held through E*TRADE Financial Corporation.

How many JAZZ shares are covered by this Form 144 notice?

The notice covers 3,507 shares of Jazz Pharmaceuticals plc common stock. These shares are associated with restricted stock vesting designated as compensation.

What is the aggregate market value of the JAZZ shares in this Form 144?

The Form 144 states an aggregate market value of $857,602.00 for the 3,507 shares of Jazz Pharmaceuticals plc common stock covered by the proposed sale.

When is the proposed sale date for the JAZZ shares under this Form 144?

The proposed sale date for the Jazz Pharmaceuticals plc (JAZZ) common shares in this Form 144 notice is August 31, 2026, with the shares to be sold on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:33 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:33 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001253886
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jazz Pharmaceuticals plc
SEC File Number	001-33500
Address of Issuer	FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD DUBLIN IRELAND D04 E5W7
Phone	353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	ENRIGHT PATRICK G
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3507	857602.00	64914577	08/31/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/28/2026	RESTRICTED STOCK VESTING	ISSUER			3507	08/28/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/31/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Paz Dizon by power of attorney for Patrick G. Enright
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)